Objective: The aim of the present retrospective population-based study was to investigate the oncologic impact of uterine and ovarian preservation (OP) in premenopausal women with stage IA or IC ovarian clear cell carcinoma (OCCC). Methods: The National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database was accessed and a cohort of surgically-staged premenopausal women (age <50 years) diagnosed with unilateral stage IA or IC OCCC was drawn. Based on site-specific surgery codes, women who did not undergo hysterectomy and/or bilateral salpingo-oophorectomy (BSO) were identified. Overall survival (OS) and cancer-specific survival (CSS) rates were calculated following generation of Kaplan-Meier curves; comparisons were made with the log-rank test. Multivariate Cox analysis was performed to control for possible confounders. Results: A total of 741 premenopausal women who met the inclusion criteria were identified. Based on available information, rate of uterine preservation was 14.5% (96/663) while the rate of OP was 28.1% (71/253). Five-year CSS rates were 90.8% for women who did not undergo hysterectomy compared with 87.7% for those who did (p=0.290). Similarly, 5-year CSS rates in the OP and BSO groups were 92.6% and 85%, respectively (p=0.060). After controlling for disease sub-stage (IA vs. IC), uterine or OP was not associated with a worse overall or cancerspecific mortality. Conclusion: In the present cohort, uterine and OP did not have a negative impact on oncologic outcomes. Selection criteria for fertility-sparing surgery (FSS) could be expanded to include women with stage IA OCCC.
INTRODUCTION
Ovarian cancer is a heterogenous group of tumors, each associated with unique clinicopathological and epidemiological characteristics [1] . Clear cell carcinoma (CCC) is a histologic subtype of epithelial ovarian carcinoma (EOC) accounting for approximately 5%-25% of all cases [2] . Women with CCC most commonly present with disease confined to the ovary, while an increased incidence is observed among those of Asian, especially Japanese, ancestry [2, 3] . CCC is also characterized by a relative resistance to first line platinum-based chemotherapy and can frequently arise from endometriotic foci [2, 3] .
Since randomized trials on the safety of FSS for early stage EOC have not been performed, evidence supporting the safety of FSS for premenopausal women with CCC mainly derives from single institutional case-control studies plagued by small sample sizes and inadequate statistical power [9] [10] [11] [12] [13] . A recent comprehensive systematic review identified only 115 patients with early stage CCC who underwent FSS [6] . Given the paucity of evidence, the aim of the present retrospective study was to investigate the oncologic impact of uterine and ovarian preservation (OP) in premenopausal women with stage IA or IC ovarian CCC (OCCC) using a multi-institutional, population-based database. Moreover, in a secondary analysis we evaluated the prevalence of regional lymph node (LN) metastasis among premenopausal women with stage I apparent OCCC who are potential candidates for FSS.
MATERIALS AND METHODS
In the present retrospective study, a cohort of premenopausal women (age <50 years) diagnosed between 1988-2013 with a primary ovarian tumor was drawn from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) database. In the present study, data deriving from 18 cancer registries were included (Detroit, Iowa, Kentucky, Louisiana, Utah, Connecticut, New Jersey, Atlanta, Rural and Greater Georgia, Alaska, California, Hawaii, Los Angeles, New Mexico, San Francisco, San Jose, and Seattle), which cover approximately 27.8% of the total US population based on the 2010 census [14] . All patient data are de-identified and available to the public for research purposes. An exemption was also granted from obtaining institutional review board approval.
Using the 3rd edition of International Classification of Diseases for Oncology (ICD-O-3)/World Health Organization (WHO) 2008 site code "C.569/ovary" and the ICD-O-3 morphology codes "8310-8313/3, 9110/3" as grouped by the International Agency for Research on Cancer (IARC), cases of OCCC were identified [15] . Women with a history of a previous primary tumor at another site, those with bilateral tumors, without microscopic tumor confirmation or active follow-up as well as women who did not undergo cancer-directed surgery were excluded from the present study. Only those with the International Federation of Gynecology and Obstetrics (FIGO) stage IA or IC disease were selected for further analysis. Based on site-specific surgery codes the nature of cancer-directed surgery was assessed and women who did not undergo hysterectomy and/or BSO were identified. A flowchart with the patient selection process is presented in Fig. 1 . For analysis purposes, year of diagnosis was dichotomized into 1988-2003 and 2004-2013 based on the year of publication of the Adjuvant ChemoTherapy in Ovarian Neoplasm (ACTION) and International Collaborative Ovarian Neoplasm Trial 1 (ICON1) studies on the value of adjuvant chemotherapy in early stage epithelial ovarian cancer [16] .
Primary outcome of interest was death from ovarian cancer (cancer-specific survival, CSS) while secondary outcome was death from any cause (overall survival, OS). The SEER database does not collect information on tumor recurrence precluding us from investigating progression free survival. Five-year OS and CSS rates were estimated following generation of Kaplan-Meier curves. For the estimation of CSS, women who died from causes other than ovarian cancer were censored. Patients who were alive with <1 months of follow-up were excluded from the survival analysis. Univariate comparison of OS and CSS was performed with the log-rank test. Moreover, Cox multivariate models were constructed to evaluate the effect of uterine and OP on mortality after controlling for possible confounders. Variables that were statistically significantly (or approached statistical significance) associated with survival by univariate analysis were selected for entry in the multivariate model. For the estimation of the prevalence of LN metastasis among premenopausal women with stage I apparent disease (T1/Nx/M0) information deriving from the histopathology report was evaluated to identify those who underwent LN dissection (LND) (Fig. 3) . Similarly, the 5-year OS rate were 89.3% and 87.2% in the uterine preservation and hysterectomy groups respectively (p=0.420 from log-rank test 3 . CSS of premenopausal women with unilateral CCC confined to the ovary stratified by performance of hysterectomy (n=564 and n=94 in the hysterectomy and uterine preservation groups, respectively; p=0.290 from the log-rank test). CCC, clear cell carcinoma; CSS, cancer-specific survival.
( Fig. 4) . 
DISCUSSION
To our knowledge this is the first population-based study focusing on the safety of FSS for women with FIGO stage I OCCC. Even after controlling for disease sub-stage neither uterine nor OP was associated with a worse overall or cancer-specific mortality. In addition, we demonstrated that the prevalence of regional LN metastasis in this population can be as high as 5.1%.
During the past years an increasingly number of reports on FSS for EOC has been published [6] . In accordance to this trend, we observed a significant increase in the rate of uterine and OP per study period. The selection criteria for FSS have not been yet definitively established given the lack of evidence from randomized trials. Current clinical guidelines of the European Society of Medical Oncology (ESMO) suggest that premenopausal women with stage IA or IC unilateral tumors and favorable histological characteristics, such as mucinous, serous, endometrioid or mixed histology and grade 1 or 2, are candidates for FSS only following a thorough staging procedure that includes lymphadenectomy [7] .
Clear cell histology has long been considered a contra-indication for FSS given that it can be associated with poorer outcomes compared to other histologic subtypes [8] . However, several retrospective studies have investigated the safety of FSS for premenopausal women with stage I OCCC, most in terms of recurrence rate [6] . Only 2 studies have evaluated the long-term survival of these women [10, 12] . In a recent case-control study, Park et al. [10] compared the oncologic outcomes of 22 premenopausal women (mean age, 36.5 years) with stage I OCCC who had FSS to a group of 25 patients who had radical surgery (mean age, 40.9 years). Similar to our results, after a median follow-up of 72 months no difference was noted in disease-free survival (DFS) or OS between the 2 groups, even following stratification by disease sub-stage [10] . Moreover, all women in the FSS group resumed normal menstruation and 27% had a 5 . CSS of premenopausal women with unilateral CCC confined to the ovary stratified by performance of BSO (n=69 and n=181 in the USO and BSO groups, respectively; p=0.060 from the log-rank test). BSO, bilateral salpingo-oophorectomy; CCC, clear cell carcinoma; CSS, cancer-specific survival; USO, unilateral salpingo-oophorectomy.
live birth [10] . A major advantage of that study was that the majority of patients in the FSS group underwent thorough staging that included lymphadenectomy (86%) and omentectomy (91%) [10] . In another retrospective case-control study, Kajiyama et al. [12] , compared the OS and progression free survival of 16 premenopausal women (median age, 35 years) to that of 205 women of all ages (median age, 54 years) who had radical surgery and did not find any differences. However, in the radical surgery group only 17 patients were ≤40 years and as in other case-series, LND and omentectomy were optional for patients undergoing FSS and rarely performed [11, 12] .
A recent comprehensive literature review identified a total of 115 women with early stage OCCC who had FSS with a cumulative relapse rate of 17% [6] . While authors suggested that FSS could potentially be offered to women with stage I CCC, they noted that the majority of recurrences were at an extra-ovarian location occurring within the first 2 years following initial surgical staging, a finding with significant implications for the management of these patients [6] . Whether the preserved ovary or uterus is the source of the recurrence remains in question [6] . Consistent with these results, in the present cohort the majority of cancer-related deaths in the uterine (88%) and OP (100%) group occurred within 5 years from initial tumor diagnosis.
An important clinical question is the safety of FSS in women with stage IC OCCC. There remains significant variability in treatment recommendations for this group. In their systematic review Satoh and Yoshikawa [18] , calculated a cumulative relapse rate of 22.6% (7/31) for women with stage IC compared with 11.1% (3/27) for those with stage IA disease.
The authors concluded that FSS should not be recommended for stage IC disease, due to poor recurrence-free survival rates. Likewise, the Gynecologic Cancer Intergroup (GCIG) consensus committee on OCCC suggests that FSS should be considered only for women with stage IA disease [19] . On the other hand, the National Cancer Network guidelines pose no limitation on the use of FSS by disease sub-stage (IA or IC) [20] . The key consideration in this scenario is not whether patients with stage IC disease have lower survival compared with stage IA, but whether FSS has an independent negative oncologic impact. In our sub-analysis, while 5-year OS and CSS rates of women who underwent FSS were lower compared to those with stage IA disease (all were below 90% and as low as 77.5% for women with a preserved uterus), they were comparable to those who underwent radical surgery. The small number of patients included in each analysis stratified by disease sub-stage, however, limited the power and increased the likelihood of a type II error.
While our findings support the safety of FSS in women with both stage IA and IC diseases, we believe the total number of cases published is insufficient and the clinical heterogeneity too significant to draw firm conclusions on the safety of FSS for any sub-stage of OCCC. Prospective multi-institutional collaborations can potentially shed light on the safety of this approach. With great interest, we await the primary results of the Japan Clinical Oncology Group Study (JCOG) non-randomized phase III trial that recruits adequately staged patients with stage IA CCC who undergo FSS and receive standard adjuvant carboplatinum-paclitaxel chemotherapy [21] .
Another important clinical question is the role of LND for women undergoing FSS for EOC [22] . In our cohort of FIGO stage I OCCC, LND was not associated with improved OS or CSS, refuting a therapeutic benefit of lymphadenectomy. The procedure, however, still plays an important role in the assessment of disease spread and guiding adjuvant treatment. Even though occult LN metastases for women with apparent stage I mucinous tumors are extremely rare [23] , in our study the calculated incidence of LN metastasis for premenopausal women with stage I apparent OCCC was not negligible (ranging from 3.6%-5.1% depending on the extent of LND).
A major strength of the present study is the large number of women undoing fertility-preserving surgical procedures. In addition, follow-up of the FSS cases was long enough (median follow-up 6.8 and 7.4 years in the uterine and OP groups, respectively) to investigate the long-term CSS and OS impact. However, several limitations should be noted. First, due to the lack of central pathology review, tumor misclassification remains a possibility. Moreover, even though all patients with OCCC routinely receive chemotherapy, according to major guidelines, we can hypothesize that women with uterine and OP should have been even more likely to receive adjuvant chemotherapy. Nevertheless, the SEER database does not report information on the use of chemotherapy, as such we could not control for its administration. Lastly, we could not verify whether all staging procedures were performed in high volume centers.
In the present retrospective population-based cohort of premenopausal women with stage IA or IC OCCC, uterine and OP did not have a negative impact on oncologic outcomes, especially for those with stage IA disease. Selection criteria for FSS could potentially be expanded to include women with stage IA OCCC. A large number of cases should be accumulated before making any final recommendations. Providers should understand the limitations of the current evidence and proceed with FSS only for women with a strong desire to perceive fertility, following extensive counseling. The creation of an international registry of women with EOC and high-risk characteristics, such as OCCC, who undergo FSS could further elucidate the safety of this approach.
